MX364732B - Vacuna contra el tumor de wilms 1. - Google Patents

Vacuna contra el tumor de wilms 1.

Info

Publication number
MX364732B
MX364732B MX2015007573A MX2015007573A MX364732B MX 364732 B MX364732 B MX 364732B MX 2015007573 A MX2015007573 A MX 2015007573A MX 2015007573 A MX2015007573 A MX 2015007573A MX 364732 B MX364732 B MX 364732B
Authority
MX
Mexico
Prior art keywords
seq
protein
nucleic acid
acid sequence
fragment
Prior art date
Application number
MX2015007573A
Other languages
English (en)
Other versions
MX2015007573A (es
Inventor
David B Weiner
Jian Yan
Jewell Walters
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2015007573A publication Critical patent/MX2015007573A/es
Publication of MX364732B publication Critical patent/MX364732B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001152Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153Wilms tumor 1 [WT1]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una molécula de ácido nucleico aislada, caracterizada porque comprende una o más secuencia de ácido nucleico seleccionadas del grupo que consiste de: (i) una secuencia de ácido nucleico que codifica la proteína establecida en la SEQ ID NO: 2, (ii) una secuencia de ácido nucleico que codifica un fragmento de la proteína establecida en la SEQ ID NO: 2 en donde el fragmento comprende al menos 90% de la longitud completa de la proteína establecida en la SEQ ID NO: 2; (iii) una secuencia de ácido nucleico que codifica una proteína que es al menos 90% idéntica a la proteína establecida en la SEQ ID NO: 2 sobre la longitud completa de la SEQ ID NO: 2; (iv) una secuencia de ácido nucleico que codifica un fragmento de una proteína que es al menos 98% idéntica a la proteína establecida en la SEQ ID NO: 2 en donde la longitud del fragmento es al menos 90% de la longitud completa de la proteína establecida en la SEQ ID NO: 2; (v) una secuencia de ácido nucleico que codifica la proteína establecida en la SEQ IE NO: 4; (vi) una secuencia de ácido nucleico que codifica un fragmento de SEQ ID NO: 4 en donde el fragmento comprende al menos 90% de la longitud completa de la proteína establecida en la SEQ ID NO: 4; (vii) una secuencia de ácido nucleico que codifica una proteína que es al menos 98% idéntica a la proteína establecida en la SEQ ID NO: 4 sobre la longitud completa de la SEQ ID NO: 4; y (viii) una secuencia de ácido nucleico que codifica un fragmento de una proteína que es 98% idéntica a la proteína establecida en la SEQ ID NO: 4 en donde la longitud del fragmento es al menos 90% de la longitud completa de la proteína establecida en la SEQ ID NO: 4.
MX2015007573A 2012-12-13 2013-12-13 Vacuna contra el tumor de wilms 1. MX364732B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737094P 2012-12-13 2012-12-13
PCT/US2013/075141 WO2014093897A1 (en) 2012-12-13 2013-12-13 Wt1 vaccine

Publications (2)

Publication Number Publication Date
MX2015007573A MX2015007573A (es) 2016-03-15
MX364732B true MX364732B (es) 2019-05-06

Family

ID=50935008

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007573A MX364732B (es) 2012-12-13 2013-12-13 Vacuna contra el tumor de wilms 1.

Country Status (12)

Country Link
US (3) US10220082B2 (es)
EP (2) EP3782640A1 (es)
JP (4) JP6523174B2 (es)
KR (3) KR102258021B1 (es)
CN (1) CN104812401B (es)
AU (1) AU2013358947B2 (es)
BR (1) BR112015013004B1 (es)
CA (1) CA2888648C (es)
MX (1) MX364732B (es)
PL (1) PL2931304T3 (es)
SI (1) SI2931304T1 (es)
WO (2) WO2014093886A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2889723A1 (en) 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
CA2888648C (en) * 2012-12-13 2021-06-08 The Trustees Of The University Of Pennsylvania Wt1 vaccine
AU2014228405B2 (en) * 2013-03-15 2017-05-11 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
SG11201604719WA (en) * 2013-12-13 2016-07-28 Univ Pennsylvania Dna antibody constructs and method of using same
WO2016089862A1 (en) 2014-12-01 2016-06-09 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
PT3737397T (pt) * 2017-12-13 2023-02-28 Inovio Pharmaceuticals Inc Vacinas anticancro direcionadas contra prame e utilizações das mesmas
US11338028B2 (en) * 2017-12-13 2022-05-24 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting LEMD1 and uses thereof
IL310808A (en) 2021-08-13 2024-04-01 Inovio Pharmaceuticals Inc Combination therapy to treat brain cancer
WO2023201199A2 (en) * 2022-04-11 2023-10-19 The Johns Hopkins University Tuberculosis vaccines
CN115845039A (zh) * 2022-07-01 2023-03-28 可蓝赛生物医药(上海)有限公司 一种广谱多肽肿瘤疫苗组成
CN116139260A (zh) * 2023-03-02 2023-05-23 广东龄值生物科技有限公司 一种wt1肿瘤疫苗及其制备方法与应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US3805783A (en) 1971-02-12 1974-04-23 A Ismach Hand powered hypodermic jet injector gun
US4342310A (en) 1980-07-08 1982-08-03 Istvan Lindmayer Hydro-pneumatic jet injector
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4447223A (en) 1982-04-16 1984-05-08 Cct Associates Medicament implant applicator
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
AU675702B2 (en) 1993-01-26 1997-02-13 Leslie R. Coney Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5505697A (en) 1994-01-14 1996-04-09 Mckinnon, Jr.; Charles N. Electrically powered jet injector
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
JP2001520537A (ja) 1997-04-03 2001-10-30 エレクトロフェクト・アクティーゼルスカブ 医薬品と核酸の骨格筋への導入方法
HUP0004589A3 (en) 1997-06-30 2003-08-28 Centre Nat Rech Scient Improved method for transferring nucleic acid into the striped muscle and combination therefor
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
EP1100579B1 (en) 1998-07-13 2015-09-02 Inovio Pharmaceuticals, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
EP1102608A4 (en) 1998-07-13 2008-09-17 Genetronics Inc METHOD AND APPARATUS FOR THE ELECTRICALLY SUPPORTED SURFACE APPLICATION OF COSMETIC MEANS
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
WO2000067837A1 (en) 1999-05-10 2000-11-16 Gentronics, Inc. Method of electroporation-enhanced delivery of active agents
US20070037165A1 (en) * 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
CA2504593C (en) 2002-11-04 2016-08-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
EP1628749B1 (en) 2003-05-30 2019-07-31 VGXI, Inc. Devices and methods for biomaterial production
US20060216722A1 (en) * 2005-03-25 2006-09-28 Christer Betsholtz Glomerular expression profiling
ES2542141T3 (es) * 2005-10-17 2015-07-31 Sloan Kettering Institute For Cancer Research Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
ES2587980T3 (es) * 2006-02-22 2016-10-28 International Institute Of Cancer Immunology, Inc Péptido WT1 con restricción HLA-A*3303 y composición farmacéutica que lo contiene
ES2679127T3 (es) * 2007-12-05 2018-08-22 International Institute Of Cancer Immunology, Inc. Composición vacunal contra el cáncer
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
EP2603581B1 (en) 2010-08-11 2019-07-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Cocultures of cumulus cells and embryos during in vitro fertilization procedures
CA2817709C (en) 2010-11-12 2021-06-01 The Trustees Of The University Of Pennsylvania Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
JP6099573B2 (ja) * 2011-01-31 2017-03-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 新規なヘルペス抗原をコードする核酸分子、それを含むワクチン及びその使用方法
CA2861206C (en) * 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
GB2504774A (en) 2012-08-10 2014-02-12 Munster Simms Eng Ltd Diaphragm pump with integral motor housing and rear pump housing
CA2888648C (en) * 2012-12-13 2021-06-08 The Trustees Of The University Of Pennsylvania Wt1 vaccine
AU2014228405B2 (en) * 2013-03-15 2017-05-11 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
TWI548337B (zh) 2015-10-16 2016-09-01 技嘉科技股份有限公司 散熱模組、顯示卡組件及電子裝置

Also Published As

Publication number Publication date
CN104812401B (zh) 2017-10-13
SI2931304T1 (sl) 2021-11-30
JP2022048162A (ja) 2022-03-25
US11638747B2 (en) 2023-05-02
EP3782640A1 (en) 2021-02-24
JP2024150611A (ja) 2024-10-23
CN104812401A (zh) 2015-07-29
JP2016501536A (ja) 2016-01-21
BR112015013004A2 (pt) 2017-09-12
US20150328298A1 (en) 2015-11-19
US20230293653A1 (en) 2023-09-21
AU2013358947A1 (en) 2015-05-21
US10220082B2 (en) 2019-03-05
JP6523174B2 (ja) 2019-05-29
AU2013358947B2 (en) 2016-10-20
KR20150096709A (ko) 2015-08-25
JP7011241B2 (ja) 2022-01-26
JP2019115369A (ja) 2019-07-18
KR20230038607A (ko) 2023-03-20
EP2931304A1 (en) 2015-10-21
MX2015007573A (es) 2016-03-15
CA2888648C (en) 2021-06-08
AU2013358947A8 (en) 2015-05-28
EP2931304A4 (en) 2016-07-20
WO2014093886A1 (en) 2014-06-19
EP2931304B1 (en) 2021-04-28
KR20210062748A (ko) 2021-05-31
US20190255163A1 (en) 2019-08-22
BR112015013004B1 (pt) 2022-09-06
CA2888648A1 (en) 2014-06-19
PL2931304T3 (pl) 2021-11-08
KR102509444B1 (ko) 2023-03-14
HK1212919A1 (zh) 2016-06-24
KR102877281B1 (ko) 2025-10-28
KR102258021B1 (ko) 2021-06-01
WO2014093897A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
MX364732B (es) Vacuna contra el tumor de wilms 1.
MX346862B (es) Secuencias consenso de envoltura de vih y método para usar las mismas.
MX356792B (es) Elementos de regulacion de plantas y sus usos.
ES2618783T3 (es) Construcción de ADN inmunomodulador no codificante
PY18107830A (es) Variantes de alfa-amilasa y polinucleótidos que las codifican
AR094141A1 (es) Composiciones y metodos para proteinas de accion prolongada
ES2691091T3 (es) Vacuna conjugada de péptido antigénico de WT1
MX387336B (es) Enzimas de clostridium histolyticum y metodos para el uso de los mismos.
UY33665A (es) Derivado peptídico
ES2693321T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
CL2019000980A1 (es) Oligonucleotidos antisentido de al menos 10 nucleotidos que inhiben de la señalización del gen tgf-ii o una región del arnm que lo codifica. (divisional solicitud 201701233).
EA201500659A1 (ru) Ацетилтрансферазы и их применение для получения каротиноидов
ECSP12011577A (es) Produccion recombinante de péptidos
MX371403B (es) Moleculas de andamiaje a base de fibronectina estabilizada.
AR069821A1 (es) Composiciones y metodos de uso de la interferencia de arn para el control de nematodos
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
ES2383716T3 (es) Composiciones y métodos que utilizan ARN de interferencia de un gen del tipo OPR3 para el control de nemátodos
CY1124110T1 (el) Συνθεσεις και μεθοδοι μεταλλαγμενου παραγοντα viii
ECSP10010082A (es) Udp-glucuronil transferasa y polinucleotido de codificacion
IN2015DN03206A (es)
UY39980A (es) Manipulación de la Auto-incompatibilidad en Plantas
AR100310A1 (es) Moléculas para transporte de antígeno modular mejoradas y sus usos
AR093923A1 (es) Polipeptidos con actividad fosfolipasa c y polinucleotidos que los codifican
CU20170038A7 (es) Derivados de adrenomedulina estabililzados especialmente útiles en el tratamiento y/o prevención de trastornos cardiovasculares, edematosos y/o inflamatorios
AR091160A1 (es) Gen dirigent eg261 y sus ortologos y paralogos y sus usos en la resistencia a patogenos en plantas

Legal Events

Date Code Title Description
FG Grant or registration